Biotransformation Products of Platinum Drugs in Rat and Human Urine
Author Information
Author(s): Xia Tang, Jerry W. Hayes, Louis Schroder, William Cacini, John Dorsey, R. C. Elder, Katherine Tepperman
Primary Institution: Barrett Center for Cancer Prevention, Treatment and Research, Cincinnati, OH, USA
Hypothesis
The biotransformation products of cisplatin and carboplatin may contribute to the toxicity observed with these drugs.
Conclusion
Cisplatin and carboplatin produce different biotransformation products in urine, with cisplatin showing more complex reactions.
Supporting Evidence
- Cisplatin is effective but has significant toxicity, particularly nephrotoxicity.
- Carboplatin is used to reduce toxicity compared to cisplatin.
- Biotransformation products of cisplatin were identified in urine samples from patients.
- Diabetic rats showed different biotransformation products compared to control rats.
Takeaway
This study looks at how cancer drugs cisplatin and carboplatin change in the body and what happens to them in urine.
Methodology
The study used HPLC-ICP-MS to analyze urine samples from rats and cancer patients treated with cisplatin and carboplatin.
Limitations
The study does not fully characterize all biotransformation products or their effects on toxicity.
Participant Demographics
Included cancer patients undergoing chemotherapy and diabetic and control rats.
Want to read the original?
Access the complete publication on the publisher's website